Baidu
map

Anesthesiology:全凭静脉麻醉与吸入麻醉对乳腺癌手术患者预后影响的比较:回顾性队列研究

2019-01-30 佚名 “罂粟花”公众号

麻醉方法与癌症复发之间的关系仍存在争议。本回顾性队列研究比较了全身静脉麻醉和吸入麻醉对乳腺癌术后复发的影响。

背景与目的

麻醉方法与癌症复发之间的关系仍存在争议。本回顾性队列研究比较了全身静脉麻醉和吸入麻醉对乳腺癌术后复发的影响。

方  法

本研究回顾了2005年1月至2013年12月间在三级教学医院接受乳腺癌手术的患者的电子病历。根据手术采用的是静脉麻醉或吸入麻醉进行分组。倾向评分匹配用于解释基线特征的差异。建立Kaplan Meier生存曲线,评估麻醉方法对术后复发时间和总生存率的影响。比较两种麻醉的癌症复发风险和全因死亡率。

结 果

研究期间7678例乳腺癌患者中,有5331例患者资料可供分析,全凭静脉麻醉组,n = 3085; 吸入麻醉组,n = 2246)。经过倾向评分匹配后,每组仍然有1766例患者。Kaplan Meier生存曲线显示两组术后复发时间及总生存率无显着差异,全凭静脉麻醉组术后5年复发情况93.2% (95% CI, 91.9 ~ 94.5),吸入组术后5年复发情况93.8% (95% CI, 92.6 ~ 95.1)。吸入麻醉与全凭静脉麻醉相比,对术后复发时间(风险比0.96;95% CI, 0.69到1.32;P = 0.782)或总生存率(风险比0.96;95% CI, 0.69 ~ 1.33, P = 0.805)无显着影响。

结 论

本研究发现麻醉方法与乳腺癌的长期预后无差异。

原始出处:

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2051338, encodeId=a2772051338a9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Feb 08 16:23:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038299, encodeId=ef5d203829998, content=<a href='/topic/show?id=4d0999208f8' target=_blank style='color:#2F92EE;'>#静脉麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99208, encryptionId=4d0999208f8, topicName=静脉麻醉)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Jan 06 10:23:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697844, encodeId=86df169e84429, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 14:23:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692035, encodeId=d906169203587, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Sep 15 21:23:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588352, encodeId=1906158835201, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jan 31 23:23:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2051338, encodeId=a2772051338a9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Feb 08 16:23:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038299, encodeId=ef5d203829998, content=<a href='/topic/show?id=4d0999208f8' target=_blank style='color:#2F92EE;'>#静脉麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99208, encryptionId=4d0999208f8, topicName=静脉麻醉)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Jan 06 10:23:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697844, encodeId=86df169e84429, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 14:23:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692035, encodeId=d906169203587, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Sep 15 21:23:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588352, encodeId=1906158835201, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jan 31 23:23:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2051338, encodeId=a2772051338a9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Feb 08 16:23:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038299, encodeId=ef5d203829998, content=<a href='/topic/show?id=4d0999208f8' target=_blank style='color:#2F92EE;'>#静脉麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99208, encryptionId=4d0999208f8, topicName=静脉麻醉)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Jan 06 10:23:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697844, encodeId=86df169e84429, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 14:23:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692035, encodeId=d906169203587, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Sep 15 21:23:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588352, encodeId=1906158835201, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jan 31 23:23:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-07-29 fusion
  4. [GetPortalCommentsPageByObjectIdResponse(id=2051338, encodeId=a2772051338a9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Feb 08 16:23:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038299, encodeId=ef5d203829998, content=<a href='/topic/show?id=4d0999208f8' target=_blank style='color:#2F92EE;'>#静脉麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99208, encryptionId=4d0999208f8, topicName=静脉麻醉)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Jan 06 10:23:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697844, encodeId=86df169e84429, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 14:23:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692035, encodeId=d906169203587, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Sep 15 21:23:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588352, encodeId=1906158835201, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jan 31 23:23:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=2051338, encodeId=a2772051338a9, content=<a href='/topic/show?id=95f8e042dd' target=_blank style='color:#2F92EE;'>#EST#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=63, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7042, encryptionId=95f8e042dd, topicName=EST)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=e9a6357, createdName=xiangyuzhou971, createdTime=Fri Feb 08 16:23:00 CST 2019, time=2019-02-08, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2038299, encodeId=ef5d203829998, content=<a href='/topic/show?id=4d0999208f8' target=_blank style='color:#2F92EE;'>#静脉麻醉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=97, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99208, encryptionId=4d0999208f8, topicName=静脉麻醉)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdqq.qlogo.cn/qqapp/1103841572/3239AC2A9C7E6019A0BC3C0489A21F7A/100, createdBy=c6a52500178, createdName=41514487@qq.com, createdTime=Mon Jan 06 10:23:00 CST 2020, time=2020-01-06, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1697844, encodeId=86df169e84429, content=<a href='/topic/show?id=f2399910109' target=_blank style='color:#2F92EE;'>#静脉#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99101, encryptionId=f2399910109, topicName=静脉)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0bc129907796, createdName=fusion, createdTime=Mon Jul 29 14:23:00 CST 2019, time=2019-07-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1692035, encodeId=d906169203587, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=72, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Sun Sep 15 21:23:00 CST 2019, time=2019-09-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1588352, encodeId=1906158835201, content=<a href='/topic/show?id=1cb8e014e0' target=_blank style='color:#2F92EE;'>#ESI#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=0, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7014, encryptionId=1cb8e014e0, topicName=ESI)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=f4f817593223, createdName=skhzy, createdTime=Thu Jan 31 23:23:00 CST 2019, time=2019-01-31, status=1, ipAttribution=)]
    2019-01-31 skhzy

相关资讯

Genet Med:剑桥大学开发“全面总结面”乳腺癌风险预测工具,已进入测试

随着精准医学以及生物信息学的发展,预测和评估癌症风险的技术也在不断更新。

辉瑞积极推动乳腺癌治疗发展 创新助力提升患者信心

由中国人民健康保险股份有限公司上海分公司(PICC)与上海镁信健康科技有限公司携手推出、辉瑞中国支持的“博爱新安 -- 乳腺癌患者医疗费用补偿项目”(以下简称“博爱新安”项目)在上海启动。应对肿瘤防控的严峻态势和巨大经济负担,社会各界共同携手,将商业保险融入乳腺癌领域的治疗支付,探索创新的解决方案以满足患者健康需求。 “博爱新安 -- 乳腺癌患者医疗费用补偿项目”启动仪式 由中国人民健康保险股份

Anticancer Res:福建人乳腺癌发病率低于全国35%,原来是它的功劳

一项新的研究发现,乌龙茶可以破坏乳腺癌细胞,而且大量摄入这种茶的人患乳腺癌的风险更低。

JCO:tamoxifen的药物遗传学与代谢

tamoxifen被广泛用作早期乳腺癌患者的辅助治疗。有推测认为endoxifen(他莫昔芬的活性代谢物)的浓度比CYP2D6基因型更能预测他莫昔芬的疗效。在一项回顾性研究中,endoxifen的疗效阈值确定为5.9 ng / mL,但缺乏前瞻性研究的确认。JCO近期发表了一篇文章,研究endoxifen浓度和CYP2D6基因型与接受tamoxifen治疗的早期乳腺癌患者的临床结局之间的联系。

病例分享:双靶齐下的乳腺癌抗HER2治疗

患者女性,48岁,围绝经期。2018年7月以“发现左乳肿物半年余”为主诉入院。既往体健,否认慢性病、传染病史。

JCLA:中国汉族散发性乳腺癌患者白细胞介素18基因启动子区域多态性与易感性的相关性分析

白介素18 (IL 18)基因位于染色体11 q22.2 22.3,1,它包含许多单核苷酸多态性(single nucleotide polymorsms, SNPs),尤其是在启动子区域。在各种癌症中,白细胞介素18 137G/C, 607G/T多态性发挥多种作用。然而,关于白介素18 (IL 18)基因多态性与绝经期体重指数(body mass index, BMI)之间相互作用的研究还存在争

Baidu
map
Baidu
map
Baidu
map